274 related articles for article (PubMed ID: 35724983)
1. Practical management of the haemorrhagic complications of myeloproliferative neoplasms.
Jones E; Dillon B; Swan D; Thachil J
Br J Haematol; 2022 Nov; 199(3):313-321. PubMed ID: 35724983
[TBL] [Abstract][Full Text] [Related]
2. Acquired von Willebrand disease in myeloproliferative disorders.
van Genderen PJ; Leenknegt H; Michiels JJ; Budde U
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():79-82. PubMed ID: 8951776
[TBL] [Abstract][Full Text] [Related]
3. Acquired von Willebrand syndrome type IIA in a patient with aortic valve stenosis and myeloproliferative disorder.
Gartner V; Oehler L
Ann Hematol; 2006 Mar; 85(3):200-1. PubMed ID: 16237526
[No Abstract] [Full Text] [Related]
4. Acquired von Willebrand's disease in the myeloproliferative syndrome.
Budde U; Schaefer G; Mueller N; Egli H; Dent J; Ruggeri Z; Zimmerman T
Blood; 1984 Nov; 64(5):981-5. PubMed ID: 6333259
[TBL] [Abstract][Full Text] [Related]
5. Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation.
Stempel JM; Podoltsev NA; Zeidan AM; Lee AI; Shallis RM
Ann Hematol; 2022 Nov; 101(11):2559-2561. PubMed ID: 35984499
[No Abstract] [Full Text] [Related]
6. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?
Federici AB
J Thromb Haemost; 2008 Apr; 6(4):565-8. PubMed ID: 18221357
[No Abstract] [Full Text] [Related]
7. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):397-406. PubMed ID: 31808903
[TBL] [Abstract][Full Text] [Related]
8. Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis.
Ido K; Nakane T; Tanizawa N; Makuuchi Y; Okamura H; Koh S; Nanno S; Nishimoto M; Hirose A; Nakamae M; Nakashima Y; Koh H; Hino M; Nakamae H
Intern Med; 2020 Nov; 59(21):2751-2756. PubMed ID: 32641652
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
[TBL] [Abstract][Full Text] [Related]
10. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
[TBL] [Abstract][Full Text] [Related]
11. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.
Mohri H
J Thromb Thrombolysis; 2003 Jun; 15(3):141-9. PubMed ID: 14739623
[TBL] [Abstract][Full Text] [Related]
12. Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome.
Magyari F; Kracskó B; Bedekovics J; Bereczky Z; Illés Á; Schlammadinger Á
Hematology; 2021 Dec; 26(1):301-304. PubMed ID: 33663351
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of acquired von Willebrand syndrome.
Federici AB; Mannucci PM
Clin Adv Hematol Oncol; 2003 Mar; 1(3):169-75. PubMed ID: 16224398
[TBL] [Abstract][Full Text] [Related]
14. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.
Federici AB
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S48-58. PubMed ID: 16427386
[TBL] [Abstract][Full Text] [Related]
15. Acquired platelet disorders.
Casari C; Bergmeier W
Thromb Res; 2016 May; 141 Suppl 2():S73-5. PubMed ID: 27207431
[TBL] [Abstract][Full Text] [Related]
16. Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis.
Trotti C; Sant'Antonio E; Vanni D; Casetti IC; Borsani O; Pietra D; Ferretti VV; Astori C; Arcaini L; Rumi E
Hematol Oncol; 2021 Oct; 39(4):589-592. PubMed ID: 34320245
[No Abstract] [Full Text] [Related]
17. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
18. Bleeding complications after arthroscopy in a JAK2V617F-positive patient with essential thrombocythemia and acquired von Willebrand syndrome (AVWS).
Rupa-Matysek J; Lewandowski K; Lewandowska M; Wojtasińska E; Wojtaszewska ML; Walczak M; Bykowska K; Komarnicki M
Int J Hematol; 2015 Apr; 101(4):405-10. PubMed ID: 25432436
[TBL] [Abstract][Full Text] [Related]
19. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders.
Federici AB; Rand JH; Mannucci PM
Hematol J; 2001; 2(6):358-62. PubMed ID: 11920274
[No Abstract] [Full Text] [Related]
20. Acquired von Willebrand syndrome 2004: International Registry--diagnosis and management from online to bedside.
Federici AB; Budde U; Rand JH
Hamostaseologie; 2004 Feb; 24(1):50-5. PubMed ID: 15029273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
